The 2025 Academic Annual Conference of Guangdong Medical Association of Urology and 2025 Bladder Cancer Academic Conference was successfully concluded in Shenzhen from August 15-17, 2025. As an innovative leader in the field of tumor early screening, Benchmark Medical's UriFind® product made an impressive debut at this conference. Professor Huang Jian and Professor Lin Tianxin from Sun Yat-sen Memorial Hospital of Sun Yat-sen University presented the company's latest achievements and technological breakthroughs in early screening and diagnosis of urothelial cancer to participating experts, winning widespread attention from attending experts and scholars.

In the national multi-center registered clinical study, UriFind® included 1,172 statistical samples. The registered clinical study data showed that the reagent kit achieved a sensitivity of 89.74%, specificity of 92.46%, and accuracy of 91.47% for auxiliary diagnosis of urothelial cancer, enabling comprehensive assessment of bladder cancer, renal pelvis cancer, and ureteral cancer in a single test. In stratified results, its advantages in detecting early-stage, microscopic, residual, and recurrent bladder cancer were particularly prominent, providing strong evidence for early screening and diagnosis of bladder cancer.

Previous research results and multiple clinical studies have proven its significant advantages in diagnosing early-stage, microscopic, residual, and recurrent tumors, with characteristics of accuracy, sensitivity, convenience, and comprehensiveness. Meanwhile, the emergence of UriFind® can reduce the frequency of cystoscopic examinations, alleviating the burden on urothelial cancer patients.

It is understood that Guangzhou Benchmark Medical Co., Ltd. is a subsidiary of KINDSTAR GLOBAL Medical Laboratory Group, dedicated to applying tumor DNA methylation sequencing technology for early cancer diagnosis and screening. Centered around "one tube of blood" and "one tube of urine" as two main lines, the company develops products covering lung cancer, breast cancer, digestive system cancers, and urinary system cancers, representing over 70% of high-incidence cancer types, spanning the entire process of early cancer screening, early diagnosis, recurrence monitoring, and companion diagnostics. Additionally, Benchmark Medical has independently built a big data and artificial intelligence platform centered on early screening, diagnosis, and treatment of lung cancer.